These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 7681121)

  • 21. Prolonged treatment with finasteride (a 5 alpha-reductase inhibitor) does not affect bone density and metabolism.
    Matzkin H; Chen J; Weisman Y; Goldray D; Pappas F; Jaccard N; Braf Z
    Clin Endocrinol (Oxf); 1992 Nov; 37(5):432-6. PubMed ID: 1283117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Finasteride in the treatment of benign prostatic hyperplasia. A urodynamic evaluation.
    Kirby RS; Bryan J; Eardley I; Christmas TJ; Liu S; Holmes SA; Vale JA; Shanmuganathan K; Webb JA
    Br J Urol; 1992 Jul; 70(1):65-72. PubMed ID: 1379107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. From the Food and Drug Administration.
    Nightingale SL
    JAMA; 1992 Sep; 268(11):1390. PubMed ID: 1380995
    [No Abstract]   [Full Text] [Related]  

  • 24. Effects of long term treatment with finasteride (MK-906), a 5-alpha reductase inhibitor, on circulating LH, FSH, prolactin and estradiol.
    Matzkin H; Chen J; Lewyshon O; Ayalon D; Braf Z
    Horm Metab Res; 1992 Oct; 24(10):498-9. PubMed ID: 1281461
    [No Abstract]   [Full Text] [Related]  

  • 25. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia.
    Guess HA; Heyse JF; Gormley GJ
    Prostate; 1993; 22(1):31-7. PubMed ID: 7678930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [5-alpha reductase inhibitor in prostatic adenoma?].
    Heinzl S
    Med Monatsschr Pharm; 1990 Dec; 13(12):382-4. PubMed ID: 1705307
    [No Abstract]   [Full Text] [Related]  

  • 27. Laboratory monitoring of androgenic activity in benign prostate hypertrophy treated with a 5 alpha-reductase inhibitor.
    Matzkin H; Chayen R; Goldfarb H; Gilad S; Braf Z
    Clin Chem; 1992 Jul; 38(7):1304-6. PubMed ID: 1377994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is the prostate pill finally here?
    Lange PH
    N Engl J Med; 1992 Oct; 327(17):1234-6. PubMed ID: 1383817
    [No Abstract]   [Full Text] [Related]  

  • 29. Medical treatment of benign prostatic hyperplasia.
    Schmidt JD
    West J Med; 1991 Dec; 155(6):633. PubMed ID: 1725942
    [No Abstract]   [Full Text] [Related]  

  • 30. The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia.
    Tempany CM; Partin AW; Zerhouni EA; Zinreich SJ; Walsh PC
    Prostate; 1993; 22(1):39-42. PubMed ID: 7678931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Magnetic resonance imaging of the efficacy of specific inhibition of 5 alpha-reductase in canine spontaneous benign prostatic hyperplasia.
    Cohen SM; Taber KH; Malatesta PF; Shpungin J; Berman C; Carlin JR; Werrmann JG; Prahalada S; Bryan RN; Cordes EH
    Magn Reson Med; 1991 Sep; 21(1):55-70. PubMed ID: 1719333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prostatic adenoma: new drugs, new surgical techniques].
    Heinzl S
    Med Monatsschr Pharm; 1992 Dec; 15(12):362-4. PubMed ID: 1282201
    [No Abstract]   [Full Text] [Related]  

  • 33. Dual control by androgens and peptide growth factors of prostatic growth in human benign prostatic hyperplasia.
    Serio M; Fiorelli G
    Mol Cell Endocrinol; 1991 Jun; 78(1-2):C77-81. PubMed ID: 1718792
    [No Abstract]   [Full Text] [Related]  

  • 34. One-year experience in the treatment of benign prostatic hyperplasia with finasteride. The MK-906 (Finasteride) Study Group.
    J Androl; 1991; 12(6):372-5. PubMed ID: 1722792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimism expressed over prostate drug.
    Jenks S
    J Natl Cancer Inst; 1991 Dec; 83(23):1712-3. PubMed ID: 1722823
    [No Abstract]   [Full Text] [Related]  

  • 36. C19 and C21 5 beta/5 alpha metabolite ratios in subjects treated with the 5 alpha-reductase inhibitor finasteride: comparison of male pseudohermaphrodites with inherited 5 alpha-reductase deficiency.
    Imperato-McGinley J; Shackleton C; Orlic S; Stoner E
    J Clin Endocrinol Metab; 1990 Mar; 70(3):777-82. PubMed ID: 1689740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medical treatment of benign prostatic hyperplasia: 5 alpha-reductase inhibitors and alpha-adrenergic antagonists.
    Monda JM; Oesterling JE
    Mayo Clin Proc; 1993 Jul; 68(7):670-9. PubMed ID: 7688840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).
    Nickel JC; Gilling P; Tammela TL; Morrill B; Wilson TH; Rittmaster RS
    BJU Int; 2011 Aug; 108(3):388-94. PubMed ID: 21631695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Finasteride: a 5 alpha-reductase inhibitor.
    Steiner JF
    Clin Pharm; 1993 Jan; 12(1):15-23. PubMed ID: 7679063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.
    Geller J
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1552-5. PubMed ID: 1699965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.